Novartis Q4 net profit rebounds to $2.1 billion

In this Aug. 12, 2005 file photo, a man passes the Logo of Swiss pharmaceutical company Novartis at the company's headquarters in Basel, Switzerland. Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion Wednesday Jan. 23, 2013, citing the lack of a $900-million one-time charge it took in the same period the previous year. (AP Photo/Keystone, Steffen Schmidt, file)

(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Net profit during the final quarter of last year rose 72 percent from the $1.21 billion net profit posted in the final three months of 2011, when the Basel-based company took a hit from ending its clinical study into wider uses of the hypertension drug Tekturna.

The results were slightly above most analysts' expectations, lifting Novartis shares by 2.9 percent to 61.85 Swiss francs ($66.59) on the Zurich exchange by mid-morning.

Chief Executive Joseph Jimenez said Novartis has a strong range of new products coming out of its research and development pipeline—including a new infant vaccine for meningitis—and predicted net sales to grow after 2013.

Fourth-quarter sales in 2012 were almost flat at $14.83 billion compared with $14.78 billion in the same period the previous year, and sales in 2013 are expected to suffer from the expiry of patents on hypertension drug Diovan.

Novartis said Gilenya, its one-daily pill against multiple sclerosis, attained what it calls 'blockbuster status' with full-year sales of $1.2 billion in 2012.

Full-year net profit was up four percent at $9.62 billion from $9.25 billion in 2011.

Novartis expects the U.S. Food and Drug Administration to carry out an inspection during the coming months at its plant in Lincoln, Nebraska, which was shut down at the end of 2011 after officials found numerous quality-control problems. Jimenez told reporters in a conference call that in the meantime the company is relying on third-party manufacturers to ensure continued supply of products such as painkiller Excedrin across the United States.

Novartis also announced Wednesday that long-time chairman and former chief executive Daniel Vasella will leave the board at the annual shareholders' meeting at the end of February. The board is proposing that Joerg Reinhardt, currently chairman of Germany rival Bayer HealthCare AG, should replace Vasella.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New drugs shore up Novartis in Q2

Jul 19, 2012

(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines ...

Dutch hi-tech company ASML profits rise

Jan 18, 2012

ASML, key global supplier of computer chip-making systems and high-tech bellwether, Wednesday posted record sales for 2011 alongside a fourth-quarter slump of nearly 30 percent in net income.

Novartis says swine flu vaccine boosts profit

Jan 26, 2010

Swiss pharmaceutical group Novartis posted on Tuesday an 8.0-percent jump in core annual net profit for 2009, saying that business had been boosted by sales of swine flu vaccine.

Taiwan's AU Optronics sees profit up 54.6 percent

Jul 28, 2010

Taiwan's AU Optronics Corp said Wednesday its net profit in the three months to June jumped 54.6 percent over the previous quarter, partly due to strong demand for high-priced items.

Recommended for you

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.